Genetic Risk Assessment in Psychiatry

Peay, Holly

doi:10.1101/cshperspect.a036616

Cited by 8 publications

(5 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Each strategy with search dates is described in Appendix 1 (Online Supplementary Material). Disorders classified in the DSM-5 under Neurodevelopmental Disorders, such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) were excluded because more genetic research on these has been done compared to other psychiatric diagnoses, to the point that they are often factored into genetic counseling risk assessments (Peay, 2020 ). This led to a decision that the sheer volume of research on neurodevelopmental disorders warrants a separate study.…”

Section: Methodsmentioning

confidence: 99%

Applying Genetic and Genomic Tools to Psychiatric Disorders: A Scoping Review

et al. 2021

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Applying Genetic and Genomic Tools to Psychiatric Disorders: A Scoping Review

et al. 2021

View full text Add to dashboard Cite

“…In particular, authors focus on the difficulties of vehiculating notions of dynamic and relative risk to broader patients' audiences (Chapman, 2022; Docherty et al, 2021; Slunecka et al, 2021). Because human's understanding of genetic risk is usually fixed and binary (Docherty et al, 2021), authors argue that it is possible that patients will overemphasize the significance of a high or low score while downsizing the role played by the environment and other social determinants (Peay, 2020). Furthermore, additional challenges will arise from the communication of the long‐term implications of PRS.…”

Section: Potential Harmsmentioning

confidence: 99%

“…The provision of professional counseling services is typically seen as a virtuous practice intended to minimize the series of potential harms of receiving PRS results (Ikeda et al, 2021; Manrique de Lara et al, 2019; Pinzon‐Espinosa et al, 2022). In particular, genetic counseling pre‐testing should focus on helping patients making sense of the etiology of the disease, by explaining the interplay between genetic versus lifestyle and environmental factors (Brown et al, 2022; Peay, 2020). Some authors underline how counseling about complex disease in polygenic settings would require genetic counselors to engage also with broader issues of social justice and public health (Wand et al, 2023).…”

Section: (Towards) Best Practices In the Clinicmentioning

confidence: 99%

Taking the risk. A systematic review of ethical reasons and moral arguments in the clinical use of polygenic risk scores

Andreoli,

Peeters,

Van Steen

et al. 2024

American J of Med Genetics Pt A

View full text Add to dashboard Cite

Debates about the prospective clinical use of polygenic risk scores (PRS) have grown considerably in the last years. The potential benefits of PRS to improve patient care at individual and population levels have been extensively underlined. Nonetheless, the use of PRS in clinical contexts presents a number of unresolved ethical challenges and consequent normative gaps that hinder their optimal implementation. Here, we conducted a systematic review of reasons of the normative literature discussing ethical issues and moral arguments related to the use of PRS for the prevention and treatment of common complex diseases. In total, we have included and analyzed 34 records, spanning from 2013 to 2023. The findings have been organized in three major themes: in the first theme, we consider the potential harms of PRS to individuals and their kin. In the theme “Threats to health equity,” we consider ethical concerns of social relevance, with a focus on justice issues. Finally, the theme “Towards best practices” collects a series of research priorities and provisional recommendations to be considered for an optimal clinical translation of PRS. We conclude that the use of PRS in clinical care reinvigorates old debates in matters of health justice; however, open questions, regarding best practices in clinical counseling, suggest that the ethical considerations applicable in monogenic settings will not be sufficient to face PRS emerging challenges.

show abstract

“…PPD entails profound ramifications for mothers, infants, and their partners. It has been identified as the second most common cause of mortality among postpartum women, attributable to suicide ( Peay, 2020 ). Moreover, PPD detrimentally influences caregiving practices, including breastfeeding and mother-infant interactions, potentially compromising the infant’s emotional and cognitive development.…”

Section: Introductionmentioning

confidence: 99%

The role of gut microbiota and blood metabolites in postpartum depression: a Mendelian randomization analysis

Cui,

Zhai,

Yang

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

BackgroundPostpartum depression (PPD) is a common complication of pregnancy that imposes a heavy health and economic burden on individuals, families and society. The etiology of PPD is complex and incompletely defined, and recent studies have identified an important role for gut microbiota (GM) and their metabolites in neurological disorders. However, fewer studies on GM and PPD are available and have not yielded uniform results.MethodsInstrumental variables for GM and blood metabolites were obtained from the MiBioGen consortium and metabolomics GWAS server. Single nucleotide polymorphisms (SNPs) associated with PPD phenotypes were obtained from the FinnGen consortium. Inverse variance weighted (IVW), weighted median, weighted mode, and MR-Egger methods were used to assess causal effects. Inverse MR analysis and sensitivity analysis were also utilized to improve the stability of the results.ResultsIn this study, 5 intestinal species and 24 blood metabolites causally associated with PPD were identified using MR analysis. In addition, MR analysis showed that Prevotellaceae and Bifidobacteria may reduce the risk of PPD by elevating Xanthine and 1-arachidonoylglycerophosphoinositol (LysoPI) levels.ConclusionsThis study identified GM and blood metabolites causally associated with PPD. The results of this study may provide a theoretical basis for the discovery of PPD-related biomarkers and the treatment of the disease by regulating the gut microenvironment.

show abstract

Genetic Risk Assessment in Psychiatry

Cited by 8 publications

References 53 publications

Applying Genetic and Genomic Tools to Psychiatric Disorders: A Scoping Review

Applying Genetic and Genomic Tools to Psychiatric Disorders: A Scoping Review

Taking the risk. A systematic review of ethical reasons and moral arguments in the clinical use of polygenic risk scores

The role of gut microbiota and blood metabolites in postpartum depression: a Mendelian randomization analysis

Contact Info

Product

Resources

About